Maternal autoantibodies are a risk factor for impaired brain development in the offspring. Antibodies (AB) against the NR1 (GluN1) subunit of the N‐Methyl‐D‐Aspartate‐receptor (NMDAR) are among the most frequently diagnosed anti‐neuronal surface AB, yet little is known about effects on fetal development during pregnancy.
We established a murine model of in utero exposure to human recombinant NR1 and isotype‐matched non‐reactive control (CTL) ABs. Pregnant C57BL/6J mice were intraperitoneally injected on embryonic days 13 and 17 each with 240 μg of human monoclonal AB. Offspring were investigated for acute and chronic effects on NMDAR function, brain development and behavior.
Transferred NR1 AB enriched in the fetus and bound to synaptic structures in the fetal brain. Density of NMDAR was considerably reduced (up to ‐49.2%) and electrophysiological properties altered, reflected by decreased amplitudes of spontaneous excitatory postsynaptic currents in young neonates (‐34.4%). NR1 AB‐treated animals displayed increased early postnatal mortality (+27.2%), impaired neurodevelopmental reflexes, altered blood pH and reduced bodyweight. During adolescence and adulthood, animals showed hyperactivity (+27.8% median activity over 14 days), lower anxiety and impaired sensorimotor gating. NR1 AB caused long‐lasting neuropathological effects also in aged mice (10 months), such as reduced volumes of cerebellum, midbrain and brainstem.
The data collectively support a model in which asymptomatic mothers can harbor low‐level pathogenic human NR1 AB that are diaplacentally transferred causing neurotoxic effects on neonatal development. Thus, AB‐mediated network changes may represent a – potentially treatable – neurodevelopmental congenital brain disorder contributing to lifelong neuropsychiatric morbidity in affected children.
This article is protected by copyright. All rights reserved.Read More...